European Heart Journal: Clinical Validation Study of the PMcardio OMI AI Model
Proudly announcing the international clinical validation study of PMcardio’s ‘Queen of Hearts’ OMI AI Model in the European Heart Journal – Digital Health, showcasing AI’s role in enhancing OMI diagnosis.
We are proud to announce the publication of a pivotal clinical validation study for PMcardio’s OMI AI Model, “Queen of Hearts,” in the European Heart Journal – Digital Health. This study marks a significant advancement in the application of AI in cardiovascular medicine, specifically in the accurate diagnosis of acute Occlusion Myocardial Infarction (OMI).
Developed using a comprehensive dataset of 18,616 electrocardiograms (ECGs) from 10,543 patients suspected of Acute Coronary Syndrome (ACS), sourced from an international database with angiographically validated outcomes, the “Queen of Hearts” model has been thoroughly evaluated. This evaluation was conducted within an international cohort, comparing the AI model’s performance directly against conventional STEMI criteria and assessments made by seasoned ECG experts.
The majority of ACS cases present without typical ST-elevation, and one-third of Non-ST-elevation myocardial infarction (NSTEMI) patients have an acutely occluded culprit coronary artery, leading to poor outcomes due to delayed identification and management. The “Queen of Hearts” AI model, designed to detect acute OMI on single standard 12-lead ECGs, addresses this challenge.
The “Queen of Hearts” AI model demonstrated an impressive area under the curve (AUC) of 0.938 in identifying OMI, showcasing superior performance with an accuracy of 90.9%, sensitivity of 80.6%, and specificity of 93.7%. These figures surpass the established STEMI criteria and align closely with the proficiency of ECG experts, highlighting the model’s advanced diagnostic capabilities.
The study’s conclusions indicate that the “Queen of Hearts” AI model shows superior accuracy in detecting acute OMI compared to the STEMI criteria. This suggests its potential to improve ACS triage, ensuring appropriate and timely referral for immediate revascularisation.
This publication in the European Heart Journal – Digital Health underscores PMcardio’s dedication to enhancing cardiac care through AI and the potential of AI-powered solutions in transforming the landscape of cardiovascular diagnostics and treatment.
For more details, we invite you to read the full publication available on the European Heart Journal – Digital Health website.
About the Queen of Hearts:
PMcardio’s OMI AI Model, also known as the Queen of Hearts, enables physicians to detect Occlusion Myocardial Infarction (OMI) from any 12-lead ECG regardless of typical ST elevation. The current gold standard misidentifies half of patients in urgent need of treatment for Acute Coronary Occlusion. The Queen of Hearts was developed and clinically validated to improve the early diagnosis of acute obstructive heart attacks in order to improve patient referral and outcomes.
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
